52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
R. C. Patel Institute of Pharmaceutical Education and Research
Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
Birla Institute of Technology
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
University of Ljubljana
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design.
Cubist Pharmaceuticals
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB.
Cubist Pharmaceuticals
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
Cubist Pharmaceuticals
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Birla Institute of Technology
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Institute of Technology & Science-Pilani
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Birla Institute of Technology
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Birla Institute of Technology
Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: structure based design, synthesis, SAR and antimicrobial activity.
University of Leeds
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
Astrazeneca
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).
Astrazeneca
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
TBA
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Astrazeneca
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
Astrazeneca India
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
University of The Sciences
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Astrazeneca R&D Boston
Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Astrazeneca
Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Birla Institute of Technology
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
University of Ljubljana
Combatting Drug-Resistant Bacteria with Gyrase and Topoisomerase IV Inhibitors: Patent Highlight.
TBA
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
Astrazeneca
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
Pfizer
Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy.
Astrazeneca R&D Boston
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
UniversitäT TüBingen
Current scenario of quinolone hybrids with potential antibacterial activity against ESKAPE pathogens.
Shandong University
Synthesis, biological and molecular modelling for 1,3,4-thiadiazole sulfonyl thioureas: bacterial and fungal activity.
Vietnam National University
Recent advances in DNA gyrase-targeted antimicrobial agents.
Queensland University of Technology
Emerging impact of triazoles as anti-tubercular agent.
Barauni (A Constituent Unit of Lalit Narayan Mithila University)
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
University of Cape Town
Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Medical School of Nanjing University
Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
University of Sassari
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Institute of Technology & Science-Pilani
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Birla Institute of Technology & Science-Pilani
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors.
Cubist Pharmaceuticals
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
Birla Institute of Technology & Science-Pilani
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Paris Diderot University
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
Pierre and Marie Curie University
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
Birla Institute of Technology and Science
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
Kyorin Pharmaceutical
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Wockhardt
Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Experimental Therapeutics Centre
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
Redx Pharma
A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity.
Csir-Central Institute of Medicinal and Aromatic Plants (Csir-Cimap)
Synthesis and antimycobacterial activity of 1-(β-d-Ribofuranosyl)-4-coumarinyloxymethyl- / -coumarinyl-1,2,3-triazole.
University of Delhi
New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
University of Ljubljana
New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Islamia College University
Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
University of Ljubljana
Kinetic characterization of a slow-binding inhibitor of Bla2: thiomaltol.
Baylor University